Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Testing effectiveness (Phase 2)Study completedNCT01498484
What this trial is testing

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Who this might be right for
EBV-induced LymphomasEBV-associated MalignanciesTransplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Atara Biotherapeutics 87
Testing effectiveness (Phase 2)Study completedNCT00002663
What this trial is testing

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Who this might be right for
EBV-induced LymphomasEBV-associated MalignanciesTransplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Atara Biotherapeutics 58